Tue, Jul 22, 2014, 6:17 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Hyperion Therapeutics, Inc. (HPTX) Message Board

  • rrtzrealmd rrtzrealmd Feb 18, 2013 12:06 PM Flag

    In my previous post...

    ...about the future 65 MILLION dollars in milestone payments and royalties HPTX may end up owing if they do manage to ever sell ravicti, I noticed another little gem in the 10Q:

    "In addition, the intellectual property license agreements executed between Ucyclyd and Dr. Marshall L. Summar (“Summar”) and Ucyclyd and Brusilow Enterprises, LLC (“Brusilow”) were assigned to the Company, and the Company has assumed the royalty and milestone obligations under the Brusilow agreement for sales of Ravicti in any indication and the royalty obligations under the Summar agreement on sales of Ravicti to treat HE. The Company will also pay Brusilow an annual license extension fee to keep the Brusilow license in effect, which extension fee is payable until the Company’s first commercial sale of Ravicti following FDA approval.
    The Brusilow and Summar agreements provide that royalty obligations will continue, without adjustment, even if generic versions of the licensed products are introduced and sold in the relevant country. "

    ..."in addition"?????...seriosusly?...as if 65 MILLION dollars weren't enough, they gotta tack on an "in addition"?...HAW!!!...

    ....more "royalty and milestone obligations" not to mention "an annual license extension fee"????...and those continue even if "even if generic versions" are introduced???????...

    ...well, doggone, talk about shareholders gettin' the short end of the stick!...HAW!!!...

    ...why, it looks like everyone EXCEPT shareholders will be making out like bandits!!!...oh, did I forgot to mention HPTX is a biotech stock?...HAW, HAW, HAW!!!...

    Sentiment: Strong Sell

 
HPTX
24.41+0.05(+0.21%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.